Cleggs Group supports businesses entering new markets and expanding into new territories through practical, commercially grounded strategy. Featured below are a selection of projects we are proud of.
Assessed a Scandinavian market-entry opportunity for Body Fit Training after the brand signed a master franchise agreement with Tage Flugeim in June 2024.
The project focused on defining a flagship-led entry model for a region where boutique fitness was still relatively underpenetrated, despite strong consumer interest in health and fitness.
The recommended rollout centred on launching in Oslo, Stockholm, and Copenhagen within the first 12 months, establishing visible proof points in the region’s leading urban fitness markets before scaling further. BFT’s public plan then targeted 20 studios within five years and at least 40 across Scandinavia over 10 years, giving the project a clear path from initial launch to regional expansion.
A major strength of the opportunity was the local operating partner. BFT said Flugeim had previously introduced Barry’s Bootcamp to Scandinavia as its first international market outside North America and expanded it to seven locations, which gave the entry plan added credibility and operational depth.
Cleggs Group contributed with partners to focus on validating the opportunity, stress-testing the rollout logic, and supporting a partner-led model that could scale beyond the initial flagship openings.
Supported the evaluation of Spirecut’s international market-expansion opportunity as the Swiss MedTech scale-up widened its commercial footprint in 2025.
The project centred on prioritising partner-led entry into new territories for a specialist surgical technology business with growing regulatory validation and increasing clinical adoption.
The expansion covered Austria, Finland, the Benelux, Poland, New Zealand, Spain, and Greece, taking Spirecut’s coverage to 20 countries across Europe, North America, the Middle East, and Asia-Pacific. The project was shaped around accelerating market access for Sono-Instruments®, Spirecut’s ultrasound-guided percutaneous instruments for carpal-tunnel syndrome and trigger finger, supported by prior FDA clearance in 2022 and CE mark approval in 2023.
A major strength of the opportunity was the combination of commercial momentum and clinical validation. Spirecut reported more than 3,000 procedures completed to date and said that over 95% of patients resumed normal daily activities within one week, giving the expansion programme stronger proof points for new-market adoption.
Cleggs Group worked with collaborators focused on validating the market opportunity, supporting territory prioritisation, and helping shape a partner-led expansion model suited to a specialist MedTech rollout.